News

Natura &Co Achieves R$ 6 Billion in Revenue, EBITDA Growth

Natura &Co Achieves R$ 6 Billion in Revenue, EBITDA Growth

Natura &Co Reports Impressive Q3 Revenue Growth

Natura &Co (B3:NTCO3) has recently unveiled its financial results for the third quarter of 2024, achieving a remarkable total revenue of R$ 6 billion. This represents an 18.5% increase compared to the same period last year. The growth was driven primarily by its subsidiary, Natura Brazil, which saw a 19.4% rise in sales. Furthermore, Avon Products Inc.'s deconsolidation during the Chapter 11 process created a challenging backdrop but did not hinder the company's overall performance.

Financial Highlights

The company reported a significant improvement in revenue on a constant currency basis, translating to an 11.3% rise when excluding Argentina's impact. The increase in revenue is attributed not only to the strong performance of Natura Brazil but also to a rebound in Avon’s operations, particularly in the Hispanic markets. Despite some regional setbacks, the overall momentum indicates a healthy recovery in sales.

Enhanced Profitability

The financial results also reveal a substantial increase in Recurring EBITDA, which reached R$ 870 million—a staggering 52% rise year-over-year, equating to a margin of 14.6%. This highlights a 340 basis point (bps) improvement, showcasing the operational efficiencies implemented across the board. A notable 43% reduction in corporate expenses further underpinned this growth, allowing for reinvestments into marketing and strategic initiatives that are expected to propel sales higher.

Operational Efficiency and Strategic Investments

In a statement, CEO Fábio Barbosa highlighted the effective integration of Natura and Avon in Latin America, applauding the positive impacts of re-investments made into marketing and technology initiatives. He emphasized that the anticipated integration in Mexico and Argentina in 2025 will be vital for enhancing the company’s margins. This integration is part of their ongoing strategy to optimize operations and leverage the strengths of both brands.

Debt Management and Sustainability Efforts

Natura &Co recently issued its 13th debenture amounting to R$ 1.3 billion, which is notable as it marks the company’s first Sustainability-Linked Bond in Brazil. This issuance focuses on performance indicators tied to the development of Amazonian bioingredients and allows the company to extend its debt maturity profile effectively, culminating in a reduced net debt to recurring EBITDA ratio of 1.5x.

Commitment to Positive Impact

The company has a strong commitment to sustainability, and as it celebrates a decade as a certified B Corp, the investments made in supporting agro-extractive communities demonstrate this commitment. Barbosa noted an impressive R$ 43 million investment made in 2023, aimed at aiding these communities, showcasing their focus on creating a positive socioeconomic impact.

Innovations in Climate Responsibility

In alignment with its Climate Transition Plan, Natura &Co has introduced 20 new biogas-powered trucks, now representing 35% of its heavy freight fleet. This initiative is projected to lead to an 82% reduction in emissions, underlining the company’s resolve to contribute to a regenerative economy while also maintaining operational efficiency.

Future Outlook

Looking forward, Natura &Co aims to leverage the momentum from this quarter's strong performance and continue implementing its integration strategies across Latin America. The consistent growth trajectory, coupled with a solid financial framework, positions Natura &Co favorably for future endeavors while enhancing its operational capabilities and market presence.

Frequently Asked Questions

What were Natura &Co's total revenues for Q3?

Natura &Co reported total revenues of R$ 6 billion for Q3 2024.

How did EBITDA perform in Q3?

The Recurring EBITDA surged to R$ 870 million, reflecting a 52% increase year-over-year.

Which areas contributed most to revenue growth?

The primary growth drivers were Natura Brazil and the recovery seen in Avon’s operations.

What sustainability measures has Natura &Co implemented?

Natura &Co introduced biogas-powered trucks and invested in supporting agro-extractive communities in the Amazon.

What is the company’s outlook for 2025?

Natura &Co expects to finalize the integration of brands in Mexico and Argentina, essential for advancing their margin recovery strategy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles